


## Supplement Appendix



**Figure S1** illustrates a representative strategy for Flow cytometric gating performed according to the International Society of Hematology and Graft Engineering (ISHAGE) guidelines \* using the following antibodies: CD45 FITC Klon: 2D1, (Beckton-Dickinson [BD] Bioscience, art. nr: 345802), CD34 PE klon: 8G12 (BD art. nr: 345808) and viability marker: Cell Viability Solution (BD Viaprobe art. no. 55816), 7-AAD (in the plot named as 7-AAD PerCP-Cy5-5).

a) Side scatter plot (SSC-A), forward scatter plot (FSC-A), exclusion of debris

b) Trucount® beads (gated)

- c) Nuclear staining 7-AAD, viable cells (gated)
- d) All viable leucocytes CD45 (Dim to bright)
- e) CD34 positive from leucocytes (P1)
- f) Lymph-blast region (gated) lymphocytes (lymf)
- g) Clustered CD45 Dim SSC<sup>low</sup> hematopoietic progenitor cells (HPC) from CD45/CD34 positive events
- h) Exclusion of events outside lymph-blast region (apoptotic cells, platelets clumps)
- i) Trucount beads<sup>®</sup> number
- j) Presents the counted number of cells as events, % of parents (as depicted in the dendrogram) and % of the total 100 000 counted cells. ##### =Not applicable

Abbreviation: A: signal amplitude,

Translation: lymfocyter: lymphocytes, viabla celler: viable cells

\* Keeney M, Chin-Yee I, Weir K, Popma J, Nayar R, Sutherland DR. Single platform flow cytometric absolute CD34+ cell counts based on the ISHAGE guidelines. International Society of Hematotherapy and Graft Engineering. *Cytometry*. 1998;34(2):61-70